Epidermal growth factor inhibition (EGFR) is emerging as an important treatment modality in
several epithelial malignancies, including head and neck squamous cell carcinoma …

The epidermal growth factor receptor (EGFR) is a validated target in squamous cell
carcinoma of the head and neck (HNSCC). However, despite high expression of EGFR in …

Targeted therapy against the epidermal growth factor receptor (EGFR) is one of the most
promising molecular therapeutics for head and neck squamous cell carcinoma (HNSCC) …

Head and neck squamous cell carcinoma (HNSCC) represent 95% of head and neck cancer
with an incidence of over half a million people globally. The prognosis for patients with …

In this review, key aspects of epidermal growth factor receptor (EGFR) biology and the fruitful
translation of these fundamental findings into recent treatment advances in head and neck …

The majority of squamous cell carcinoma of the head and neck (SCCHN) overexpress
epidermal growth factor receptor (EGFR), which has been associated with poor treatment …

Epidermal growth factor receptor (EGFR), a receptor tyrosine kinase that activates multiple
signaling pathways, including phosphatidylinositol‐3‐kinase/v‐AKT murine thymoma viral …

Introduction: As epidermal growth factor receptor (EGFR) is overexpressed in approximately
90% of squamous cell carcinomas of the head and neck (SCCHN), several therapeutic …

Head and neck squamous cell carcinoma (HNSCC) affects over half a million people
worldwide. Despite advances in therapy, only half of the patients are alive in 5years …

Over the past decade, the important role of different growth factors and their receptors and
signal transduction pathways in the genesis and progression of tumors has been well …